Invizius

Invizius

Fighting Inflammation at its Source

Founded 2018

Motherwell, United Kingdom 15 employees Series B Total: $10.15M Biotechnology, Health Care

Invizius is a biotechnology startup with the slogan "Second Generation Complement Therapeutics." The company originated from research conducted at the University of Edinburgh, Scotland. It aims to develop Second Generation Complement Therapeutics to significantly enhance the clinical outcomes of patients with Acute Kidney Injury receiving CRRT and patients on Renal replacement Therapy receiving Peritoneal Dialysis. Despite advancements in haemodialysis membranes, Complement activation by contact with a foreign surface remains a serious issue with short, medium, and long-term clinical implications. This activation has also been associated with Peritoneal Dialysis (PD) and may be a driver of fibrotic changes that limit PD duration. Founded in 2018, Invizius operates in the biotechnology and healthcare industries, with headquarters in the United Kingdom. The company recently secured a noteworthy £1.00M grant investment on 30th March 2022 from the Biomedical Catalyst Fund. This financial support positions Invizius to advance its innovative approach to addressing critical issues in acute kidney injury and renal replacement therapy. The backing from the Biomedical Catalyst Fund signifies confidence in Invizius' potential to make a significant impact in the biotechnology sector, particularly in the realm of complement therapeutics.

Funding Stage	Amount	Investors	Lead Investors	Date
Grant	£1.00M	1	Biomedical Catalyst Fund	30 Mar 2022
Series A	£5.30M	7	Downing Ventures, Scottish Enterprise +5	06 May 2021
Series A	£2.75M	2	Edinburgh Innovations, Scottish Investment Bank	11 Sep 2019
Seed Round	£500.00K	-		02 May 2018
Grant	£600.00K	-		01 Jan 2018

Funding Stage

Amount

Investors

Lead Investors

Date

Grant

£1.00M

Biomedical Catalyst Fund

30 Mar 2022

Series A

£5.30M

Downing Ventures, Scottish Enterprise +5

06 May 2021

Series A

£2.75M

Edinburgh Innovations, Scottish Investment Bank

11 Sep 2019

Seed Round

£500.00K

02 May 2018

Grant

£600.00K

01 Jan 2018

FAQ About Invizius

Fighting Inflammation at its Source

Invizius was founded in 2018.

Invizius is headquartered in Motherwell, United Kingdom.

Invizius operates in Biotechnology and Health Care. Its work centres on dialysis treatment, extra-corporeal treatments, medical research and patient outcomes.

Invizius has approximately 15 employees.

Invizius has completed 5 funding rounds, raising a total of $10.15M. The latest funding stage is Series B.

Top alternatives and competitors to Invizius include ATRO Medical BV, BioAesthetics, osteolabs GmbH, TiGenix, Clinatec. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Invizius and ATRO Medical BV are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Invizius

Funding Rounds & Investors (5)

Latest News

Invizius Alternatives & Competitors

FAQ About Invizius